Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Resource Type
Article
Authors
Jaeger, Hans ; Overton, Edgar T ; Richmond, Gary ; Rizzardini, Giuliano ; Andrade-Villanueva, Jaime Federico ; Mngqibisa, Rosie ; Hermida, Antonio Ocampo ; Thalme, Anders ; Belonosova, Elena ; Ajana, Faïza ; Benn, Paul D ; Wang, Yuanyuan ; Hudson, Krischan J ; Español, Carlos Martín ; Ford, Susan L ; Crauwels, Herta ; Margolis, David A ; Talarico, Christine L ; Smith, Kimberly Y ; van Eygen, Veerle ; Van Solingen-Ristea, Rodica ; Vanveggel, Simon ; Spreen, William R
Source
In The Lancet HIV November 2021 8(11):e679-e689
Subject
Primary Research Articles
Language
ISSN
2352-3018